



ADVANCING ACUTE-CARE THERAPEUTICS

EKR
THERAPEUTICS

Howard Weisman
Chairman & CEO



Disclosure Statements

Forward Looking Statements

EKR Therapeutics, a private company that believes strongly in the principles of fair disclosure, notes that this presentation may contain forward-looking statements that are not historical facts but are based on current expectations, estimates, assumptions, and projections. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond EKR's control and could cause actual results to differ materially from those expressed, implied or forecasted. Forward-looking statements included herein reflect EKR's views and assumptions only as of the date this presentation. Except as required by law, EKR undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Product Prescribing Information

Any reference herein to any products sold or distributed in the U.S. by EKR Therapeutics must be read and/or viewed in conjunction with the full prescribing and product safety information available on the "Products" pages of the EKR website www.ekrtx.com

Acute-Care Specialty Pharma Company

Founded in late 2005, EKR Therapeutics is dedicated to serving the needs of the acute-care hospital space by focusing on



the growth of novel products offering broader therapeutic potential to improve outcomes and patient quality of life.

Corporate Snapshot

Business Model

- **Product marketing/distribution • Selective Acquisitions • Development**

Execution

- **Accomplished management team with extensive industry expertise:**
 - Sales & marketing ▫ Manufacturing ▫ QA/QC ▫ Clinical Development
 - Medical Affairs ▫ Regulatory/FDA Affairs ▫ Business Development
- **Leverage EKR's direct field force of product specialists (~60 reps)**

Goal

- **Pre-eminent commercial operation in acute-care Rx products**
- **Double sales by 2012**
- **Create an enterprise value in excess of \$1 billion**

Financial Strength

- **>\$180 million raised in equity and debt financing since inception**
 - MPM Capital ▫ LLR Partners ▫ Quaker BioVentures ▫ NewSpring Capital
 - ESP Equity Partners ▫ GE Healthcare Services ▫ Management

Management

Name	Position	Experience
Howard Weisman	CEO & Chairman	ESP Pharma • Parke-Davis • Merck
Richard DeSimone	COO/CFO, Director	Roxitucus Ventures • Patient Care Mgmt • ESP Pharma (Advisor)
Michael J. Lerner, JD	SVP, General Counsel	Lowenstein Sandler • Reliant Pharma • Gibbons, Del Deo, Dolen, Griffinger & Vecchione
Graham May, M.D.	Chief Medical Officer	Esprit Pharma • ESP Pharma • Pharmacia • NIH • Novartis • Organon
Susan C. Bacso	SVP, Ops & Supply	Becton Dickinson • ESP Pharma • ESP Equity Partners • Merck
Ernie Biczak, M.D.	SVP, Marketing	Esprit Pharma • ESP Pharma • St. Barnabas Health Care System
Dave Iwanicki	SVP, Commercial Ops	PDL BioPharma • ESP Pharma • Eli Lilly
Stephen Hulse, R.Ph.	VP, Sales	PDL BioPharma • ESP Pharma • Organon • Knoll
Tong Zhang, Ph.D.	VP, Bus. Development	ESP Equity Partners • Credit Suisse • Defined Health

EKR Sales Team Profile

- **~60 field specialists: Hospital, National Accounts**
- **Average 5-7 years of overall experience**
-
- **1,500 accounts covered**
- **Strong record of performance over last 6 years**

Broad Reach Within Hospitals

Surgery	Critical Care/ Cardiology	Neurology	Emergency Medicine	Oncology
CT Surgeon	Interventional Cardiologist	Neuro Intensivist	Emergency Department Physician	Stem Cell Transplant
Vascular Surgeon	Clinical Cardiologist	Neurosurgeon	ED Nursing Staff	Radiation Oncology
General Surgeon	Critical Care Intensivist	Stroke Neurologist		
Trauma Surgeon	CCU Nursing Staff			
Anesthesiologist	Cath Lab Techs			
OR Staff				

Key Milestones



- **6/2006: Acquired rights to Gelclair® (oral mucositis)**
- **10/2006: Deployed field force of 10 specialty reps**
- **8/2007: Raised > \$13 million (~\$20 million cumulative)**
- **8/2007: Acquired rights to DepoDur® (post-operative pain)**
- **3/2008: Re-acquired legacy ESP Pharma Assets**
 - › Cardene® IV and SR (hypertension)
 - › Retavase® (acute myocardial infarction)
- **3/2008: Raised >\$145 million**
 - › \$50 million equity; MPM as lead
 - › \$95 million Senior Debt
- **4/2008: Integrated sales forces**
- **6/2008: Relocated HQ to 21,000 sq. ft. from 10,000 sq. ft**
- **7/2008: “Ready-to-Use” Cardene I.V. premixed bags approved**
- **11/2008: 2X concentration Cardene I.V. RTU bags approved**



Core Promoted Products

For Acute Hypertension ...

Take Control with **Cardene® I.V.**

CARDENE® I.V.
(nicardipine hydrochloride)
premixed injection

An Approved Treatment for over 15 years

New

Ready-to-Use Premixed I.V. Bag

Available in **Double (2x)** and **Single (1x)** concentrations



DEPODUR®
(morphine sulfate extended-release liposome injection) 

Recovery starts with relief.

the only extended-release morphine sulfate approved for epidural use in the treatment of postsurgical pain ...

Get Moving in the Right Direction



- **I.V. calcium channel blocker for the treatment of acute hypertension when an oral is not feasible or desirable (FDA approved 1992)**
 - Smooth, predictable and reliable blood pressure control
 - Originally available in glass ampules for dilution prior to I.V.
- **First-line treatment recommended by AHA / ECC and ASA guidelines**
- **May 2002: ESP Pharma acquires from Wyeth (\$6M run rate)**
- **Mar. 2005: PDL BioPharma acquires ESP (Cardene run rate ~ \$60M)**
- **Mar. 2008: EKR re-acquires Cardene (run rate ~ \$156M)**

NEW Ready-to-Use I.V. Bags

- **July 2008:** FDA approves premixed Cardene I.V. Ready-to-Use bags
- **Nov. 2008:** FDA approves Double (2X) concentration of RTU bags



predictable, precise, steady BP control



Now in convenient, proprietary
point-of-care delivery platform



Ampule

- Well established efficacy and safety
- Approved treatment for >15 years
- More than 900,000 patients treated


Premixed RTU Bag

- Same proven efficacy and safety
- Convenient stocking for rapid use
- Avoids medication admixing errors
- Facilitates better compliance with TJC standards

CARDENE® I.V.
(nicardipine hydrochloride)
premixed injection

Utility in All Hospital Depts.

Switching departments doesn't mean switching
antihypertensives



ED


OR

ICU

Post-Op

- **Hypertension and Hypertensive Emergencies**
 - ▣ 70+ million Americans have HTN
 - ▣ Hypertensive emergencies affects 500,000 Americans each year
- **Stroke**
 - ▣ ~750,000 ischemic and hemorrhagic strokes per year
- **Perioperative Hypertension**
 - ▣ Up to 30% - 80% of all surgical patients, particularly cardiovascular surgical patients

Solid Foundation




Source: NDC

Post-Surgical Pain Management



- **Only** FDA-approved extended-release opioid (morphine sulfate) for epidural use*
- One injection provides up to 48-hr analgesia
- Patents: 2017
- Approved by FDA in May 2004
- Licensed to EKR by Pacira in August 2007
- EKR re-launch in Q1 2008




Intrathecal space ('spinal')

* Broad Indication ...

‘for single dose administration by the epidural route, at the lumbar level, for the treatment of pain following major surgery’

Product Characteristics

- **Morphine sulfate encapsulated within DepoFoam®***
 - Multi-vesicular liposome particles
 - Ready-to-use aqueous suspension <5% lipid
 - Biodegradable and biocompatible
 - Compatible with narrow gauge needles
- **Ready-to-use extended-release of morphine**
- **Single lumbar epidural injection**
- **Available in 10 mg and 15 mg doses commercially (each at a concentration of 10 mg morphine/ml)**



*FF-SEM image of
DepoFoam particle*


* DepoFoam is a registered trademark of Pacira Pharmaceuticals

Competitive Advantages

- **A single epidural injection provides pain relief up to 48 hrs.**
- **Pain relief superior to IV PCA alone**
 - ▣ Potentially less respiratory depression
- **No indwelling epidural catheter required**
 - ▣ Simplifies nursing care
 - ▣ Avoids complication of catheter dislodgement
 - ▣ Less potential for hematoma and infection
 - ▣ Faster time to ambulation
- **Anticoagulants (e.g. LMWH) are not contraindicated**

- **Large market opportunity**
 - **More than 70 million surgical patients per year in the U.S.**
 - › Over 25% experience severe post surgical pain
- **Key market opportunities**
 - **Any major surgery requiring 48-hours of in hospital surveillance**
 - **Thoracic, abdominal, pelvic surgeries**
 - **Hip and knee arthroplasty**

Revenue Trend



2008 Financial Highlights* (\$ in millions)

Income Statement

Gross Revenues	\$ 209
EBITDA	\$ 86

Balance Sheet

Cash, equivalents, short-term investments	\$ 52
Current ratio	1.1x
Long-term debt	\$ 30
Equity	\$ 36
Debt/EBITDA	0.35x

* Estimations

EKR Growth Strategy

- **Sales and marketing of core promoted products**
 - **Organic growth opportunities**
 - › Take advantage of product synergies
 - Potential top-line & margin benefits
 - › Leverage enlarged sales force of product specialists
 - Backed by strong customer service & medical education
- **Business Development**
 - **Product acquisition/in-licensing/co-promotion**
 - › Approved products
 - › Late-stage development compounds
 - **Flexible, win-win partnership philosophy**

Business Development Strength

- **Well positioned to pursue deal/partnership opportunities**
 - Strong financial resources
 - Highly experienced cohesive team
 - Fast decision making
 - Flexible deal philosophy with best interest alignment
 - Commitment to product commercialization
- **Criteria**
 - Marketed or late-stage products
 - Synergy with existing portfolio
 - Ability to leverage commercial infrastructure

Take Away

Focus

- Acute-care specialty products
- Leverage commercial organization to acquire & exploit under-valued approved and development products

Ability to Execute Business Model

- Cohesive management team with prior success executing the EKR strategy
- Within 2 years of initiating operations:
 - 4 commercial products
 - FDA approval of 2 product line extensions
 - Organization of over 100 people
 - Commercial operations of >70 sales & marketing personnel
 - Profitable and cash flow positive

Growth Strategy

- Additional acquisitions to complement organic growth
- Double sales by 2012
- Create an enterprise value in excess of \$1 billion
- Pre-eminent commercial operation in the acute care setting



ADVANCING ACUTE-CARE THERAPEUTICS

EKR
THERAPEUTICS

EKRtx.com

